Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $700000.0.

  • AVITA Medical's Depreciation & Amortization (CF) rose 7114.91% to $700000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.3 million, marking a year-over-year increase of 10843.69%. This contributed to the annual value of $2.3 million for FY2025, which is 10843.69% up from last year.
  • Latest data reveals that AVITA Medical reported Depreciation & Amortization (CF) of $700000.0 as of Q4 2025, which was up 7114.91% from $574000.0 recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Depreciation & Amortization (CF) registered a high of $700000.0 during Q4 2025, and its lowest value of -$217000.0 during Q2 2022.
  • Over the past 5 years, AVITA Medical's median Depreciation & Amortization (CF) value was $187000.0 (recorded in 2023), while the average stood at $262894.7.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 16326.53% in 2022, then surged by 17058.82% in 2025.
  • Over the past 5 years, AVITA Medical's Depreciation & Amortization (CF) (Quarter) stood at $174000.0 in 2021, then fell by 25.29% to $130000.0 in 2022, then soared by 43.85% to $187000.0 in 2023, then surged by 118.72% to $409000.0 in 2024, then skyrocketed by 71.15% to $700000.0 in 2025.
  • Its last three reported values are $700000.0 in Q4 2025, $574000.0 for Q3 2025, and $552000.0 during Q2 2025.